Cardioprotection in Diabetes: A Changing Landscape
910 Views
Dr Jamshed J Dalal, Mumbai 06 January 2018
Holistic CV risk management in diabetes involves control of multiple CV risk factors with statins/antihypertensives/antiplatelets.
Role of the older antidiabetic agents remains controversial, although metformin provides cardioprotection. Among the newer classes, SGLT-2 inhibitors and GLP-1 agonists have demonstrated benefits in reducing CV events in diabetes.
Newer antidiabetic drugs may be considered as vasculoprotective along with glycemic control.
To comment on this article, create a free account.
Sign Up to instantly get access to 10000+ Articles & 1000+ Cases
eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.